Logan Lutton

Charlie Dragovich, Senior Director and Client Strategist at Cencora, talks about the way regulations usually work and how the road to the Preapproval Information Exchange Act was different.

An overview of the preapproval information exchange (PIE) from Charlie Dragovich, Senior Director and Client Strategist at Cencora

An optimistic outlook on the future of the biosimilar market driving down pharmaceutical drug spend.

How health plans are implementing strategies to leverage biosimilars to lower costs for both payers and patients, according to Javier Gonzalez, Pharm.D., chief growth and commercial officer of Abarca

Cynthiya Ruban, Ph.D., M.S., Director of Digital Solutions at Cencora says to keep the following in mind as AI use accelerates.

Ways AI is increasingly used in healthcare and how it can benefit healthcare decision makers, according to Cynthiya Ruban, Ph.D., M.S., Director of Digital Solutions at Cencora.

A closer look at the available PrEP options available in the United States.

Here’s what you missed this week on Managed Healthcare Executive.

Hympavzi is the first anti-tissue factor pathway inhibitor approved in the United States for hemophilia.

If approved, elinzanetant would be another non-hormonal option for menopausal women seeking hot flash relief.

More research on clinical meaningfulness is on the way, according to Stephanie Graff, M.D., FACP, FASCO.

Early trial data of two virally suppressed, breast-feeding women with HIV shows that there may be less of a risk of HIV transmission during breastfeeding than previously believed.

The International AIDS Society's meeting, AIDS 2024, the 25th International AIDS Conference, was held July 22-26 in Munich, Germany. Approximately 10,000 people attended the meeting, the largest in the world devoted to HIV and AIDS. Many of the sessions were live streamed and could be viewed remotely. Here is a sample of our coverage of the meeting.

Here’s what you missed this week on Managed Healthcare Executive.

Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute, explains the importance of the term “clinically meaningful” and shares some of the ways it can be defined.

The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by the end of this year.

Although many women are living longer after a breast cancer diagnosis, inequalities persist.

Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.

Less than a quarter of menopausal women have their menopause symptoms entered into their charts at primary care visits, resulting in missed opportunities for timely treatment.

With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that you might not know about.

Otulfi is the fourth Stelara biosimilar to be approved by the FDA.

Here’s what you missed this week on Managed Healthcare Executive.

The Democrats have expanded the program under the Affordable Care Act. Republicans have proposed cuts in federal funding and work requirements.

Employment satisfaction, sleep quality and lack of physical movement were all tied to vitality levels, survey results show.

The patient panels of physicians underrepresented in medicine (URiM) showed that they had greater odds of being a Medicaid provider than White family physicians.

Aqneursa is the second drug approved within a week to treat Niemann-Pick Disease, Type C.

The FDA has already approved Zoryve cream (0.3% and 0.15%) for plaque psoriasis and atopic dermatitis in adults and children ages 6 and up. Currently, Zoryve foam 0.3% is only approved to treat seborrheic dermatitis in adult and pediatric patients 9 years and older.

This is the first FDA approved medication for the rare and progressive neurodegenerative disease, Niemann-Pick Disease Type C.

Bimzelx was first approved last year for the treatment of moderate to severe psoriasis in adults, making it the first and only IL-17A and IL-17F inhibitor approved in the United States for four autoimmune diseases.

Here’s what you missed this week on Managed Healthcare Executive.